Citation and commencement1

Expiry of certain provisions in these RegulationsF981ZA

F69Schedules1A

InterpretationE42

• F54...

• “active implantable medical device” means a medical device which—

  1. a

     relies for its functioning on a source of electrical energy or a source of power other than that generated directly by the human body or by gravity; and

  2. b

     is intended to be totally or partially introduced into the human body (whether surgically or medically, including being introduced into a natural orifice) and which is intended to remain in the human body after completion of the surgical or medical procedure during which it is introduced,

  even if it is intended to administer a medicinal product or incorporates as an integral part a substance which, if used separately, would be a medicinal product;

• F15...

• F97“approved body” is to be construed in accordance with regulation A45;

• F68...

• F42...

• “CE marking” means a conformity marking consisting of the initials “CE”;

• F36...

• F37“clinical data” means the safety or performance information that is generated from the use of a device, derived from—

  1. a

     clinical investigations of the device concerned; or

  2. b

     clinical investigations or other studies reported in scientific literature of a similar device for which equivalence to the device in question can be demonstrated; or

  3. c

     published or unpublished reports on other clinical experiences of either the device in question or a similar device for which equivalence to the device in question can be demonstrated;

• F25“coronavirus test device” means an in vitro diagnostic medical device for the detection of the presence of a viral antigen or viral ribonucleic acid (RNA) specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);

• F78“designated standard” has the meaning given in regulation 3A;

• “device for performance evaluation” means a product which is intended by its manufacturer to be subject to one or more performance evaluation studies in laboratories for medical analysis or in other appropriate environments outside his own premises;

• F62“Directive 90/385” means Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of Member States relating to active implantable devices F35as it had effect immediately before IP completion day;

• F23“Directive 93/42” means Council Directive 93/42/EEC of 14 June 1993 concerning medical devices F10as it had effect immediately before IP completion day;

• F7“Directive 98/79” means Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in-vitro diagnostic medical devices F84as it had effect immediately before IP completion day;

• F17...

• F41“Directive 2003/12” means Commission Directive 2003/12 of 3rd February 2003 on the reclassification of breast implants in the framework of Directive 93/42/EEC concerning medical devices;

• F83...

• F9“Directive 2005/50” means Commission Directive 2005/50/EC of 11 August 2005 on the reclassification of hip, knee and shoulder joint replacements in the framework of Council Directive 93/42/EEC concerning medical devices;

• F28“Directive 2007/47” means Directive 2007/47/EC of the European Parliament and of the Council amending Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, Council Directive 93/42/EEC concerning medical devices and Directive 98/8/EC concerning the placing of biocidal products on the market;

• F103...

• “F47... CAB” shall be construed in accordance with regulation 48(1);

• F58...

• F60...

• F32...

• F73“hazard” means a potential source of injury or damage to health;

• F105“hip, knee or shoulder replacement” means an implantable component part of a total joint replacement system which is intended to provide a function similar to that of either a natural hip joint, a natural knee joint or a natural shoulder joint, other than ancillary components (screws, wedges, plates and instruments);

• F49“intended for clinical investigation” means—

  1. a

     intended for use by a registered medical practitioner when conducting investigations of that device in an adequate human clinical environment; or

  2. b

     intended for use by any other person in F91Great Britain who, by virtue of their professional qualification, is authorised to carry out investigations of that device in an adequate human clinical environment;

• “intended purpose” means—

  1. a

     in relation to an active implantable medical device, the use for which it is intended and for which it is suited according to the data supplied by the manufacturer in the instructions relating to it;

  2. b

     in relation to any other medical device, the use to which the device is intended according to the data supplied by the manufacturer on the labelling, the instructions for use and/or the promotional materials;

• “in vitro diagnostic medical device” means a medical device which—

  1. a

     is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination; and

  2. b

     is intended by the manufacturer to be usedin vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information—

     1. i

        concerning a physiological or pathological state,

     2. ii

        concerning a congenital abnormality,

     3. iii

        to determine the safety and compatibility of donations, including blood and tissue donations, with potential recipients, or

     4. iv

        to monitor therapeutic measures,

     and includes a specimen receptacle but not a product for general laboratory use, unless that product, in view of its characteristics, is specifically intended by its manufacturer to be used forin vitro diagnostic examination;

• F43“machinery” has the meaning given to it by F71regulation 4 of the Supply of Machinery (Safety) Regulations 2008;

• “manufacturer” means—

  1. a

     the person with responsibility for the design, manufacture, packaging and labelling of a device before it is placed on the market under his own name, regardless of whether these operations are carried out by that person himself or on his behalf by a third party; or

  2. b

     any other person who assembles, packages, processes, fully refurbishes or labels one or more ready-made products or assigns to them their intended purpose as a device with a view to their being placed on the market under his own name, apart from a person who assembles or adapts devices already on the market to their intended purpose for an individual patient;

• “medical device” means F92any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, together with any accessories, including the software intended by its manufacturer to be used specifically for diagnosis or therapeutic purposes or both and necessary for its proper application, which—

  1. a

     is intended by the manufacturer to be used for human beings for the purpose of-

     1. i

        diagnosis, prevention, monitoring, treatment or alleviation of disease,

     2. ii

        diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap,

     3. iii

        investigation, replacement or modification of the anatomy or of a physiological process, or

     4. iv

        control of conception; and

  2. b

     does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, even if it is assisted in its function by such means,

  and includes devices intended to administer a medicinal product or which incorporate as an integral part a substance which, if used separately, would be a medicinal product and which is liable to act upon the body with action ancillary to that of the device;

• “the Medical Devices Directives” means Directive 90/385, Directive 93/42, F80both read with Regulation (EU) No 207/2012 and Regulation (EU) No 722/2012 and Directive 98/79;

• F13...

• “medicinal product” has the meaning given in F38regulation 2(1) of the Human Medicines Regulations 2012;

• F20“mutual recognition agreement” means an agreement that—

  1. a

     is between the United Kingdom and a country listed in Schedule 2, and

  2. b

     covers matters including the conditions under which the United Kingdom and F1that country will accept or recognise the results of conformity assessment procedures undertaken by the each other's designated bodies;

• F88...

• F4...

• F51...

• “placing on the market” means, in relation to a medical device, the first making available in return for payment or free of charge of a new or fully refurbished device, other than a device intended for clinical investigation, with a view to distribution, use, or both, on the F12Great Britain market F29and related expressions must be construed accordingly;

• “putting into service” means—

  1. a

     in relation to an active implantable medical device, the making available of the device to a registered medical practitioner for implantation;

  2. b

     in relation to any other medical device, the first making available of the device in F77Great Britain to a final user, including where a device is used in a professional context for the purposes of medical analysis without being marketed;

• F45“Regulation (EU) No 207/2012” means Commission Regulation (EU) No 207/2012 of 9 March 2012 on electronic instructions for use of medical devices;F19(as retained under section 3 of the European Union Withdrawal Act 2018 and modified under section 8 of that Act)

• “Regulation (EU) No 722/2012” means Commission Regulation (EU) No 722/2012 of 8 August 2012 concerning particular requirements as regards the requirements laid down in Council Directives 90/385/EEC and 93/42/EEC with respect to active implantable medical devices and medical devices manufactured utilising tissues of animal origin; F95(as retained under section 3 of the European Union Withdrawal Act 2018 and modified under section 8 of that Act)

• F46“Regulation (EU) 2017/745” means Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC;

• F46“Regulation (EU) 2017/746” means Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU;

• F143“Regulation (EU) 2022/1107” means Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 of the European Parliament and of the Council;

• “relevant essential requirements”, in relation to a medical device, means the essential requirements set out in Annex 1 of Directive 90/385, Annex I of Directive 93/42 or Annex I of Directive 98/79 which apply to it, but not including, in the case of a device intended for clinical investigation, such of those requirements, or aspects of them, as are the subject of the investigation;

• “specimen receptacle” means a medical device which (whether vacuum-type or not) is specifically intended by its manufacturer to be used for the primary containment and preservation of specimens derived from the human body for the purpose ofin vitro diagnostic examination;

• “stable derivatives device” means a medical device that contains human blood, blood products, plasma or blood cells of human origin, and which incorporates, as an integral part, a substance which—

  1. a

     if used separately, may be considered to be a medicinal product constituent or a medicinal product derived from human blood or human plasma within the meaning of F3regulation 2(2) of the Human Medicines Regulations 2012; and

  2. b

     is liable to act upon the human body with action ancillary to that of the device;

• F99“statistical review” means a review of the statistical sections of the written notice which a manufacturer or their UK responsible person submits to the Secretary of State pursuant to regulation 16(1) or 29(1) in respect of an intended clinical investigation of a relevant device;

• “supply”, in relation to a medical device, means—

  1. a

     the supply of, or the offer or agreement to supply, the device; or

  2. b

     the exposure or possession for supply of the device;

• F86“third country conformity assessment body” means a body established in a country which is listed in Schedule 2 and designated in accordance with a relevant mutual recognition agreement to carry out conformity assessment procedures for the purposes of these Regulations;

• F89...

• F64“UK marking” has the meaning given in Article 2(22) of Regulation (EC) No 765/2008; and

• F50...

• F90“UK responsible person” means a person established in any part of the United Kingdom who acts on behalf of a manufacturer established outside the United Kingdom in relation to specified tasks with regard to the manufacturer's obligations under these regulations.

InterpretationE12

• F54...

• “active implantable medical device” means a medical device which—

  1. a

     relies for its functioning on a source of electrical energy or a source of power other than that generated directly by the human body or by gravity; and

  2. b

     is intended to be totally or partially introduced into the human body (whether surgically or medically, including being introduced into a natural orifice) and which is intended to remain in the human body after completion of the surgical or medical procedure during which it is introduced,

  even if it is intended to administer a medicinal product or incorporates as an integral part a substance which, if used separately, would be a medicinal product;

• F114...

• “Association Agreement” means an Agreement, listed in Schedule 1, establishing an Association between the European Communities and their Member States, on the one part, and another State on the other part (referred to in these Regulations as a “State which is a Party to an Association Agreement”) on Conformity Assessment and Acceptance of Industrial Products;

• F8“authorised representative” means a person established within a relevant state, explicitly designated by the manufacturer who is not a person established in a relevant state, who acts for the manufacturer and may be addressed by authorities and bodies in a relevant state instead of the manufacturer with regard to the latter’s obligation under Directive 90/385, Directive 93/42 and Directive 98/79;

• “CE marking” means a conformity marking consisting of the initials “CE”;

• “the Community” means—

  1. a

     in the context of any requirement relating to an in vitro diagnostic medical device, the F113European Union;

  2. b

     in the context of any requirement relating to any other medical device, the European Economic Area;

• F132“clinical data” means the safety or performance information that is generated from the use of a device, derived from—

  1. a

     clinical investigations of the device concerned; or

  2. b

     clinical investigations or other studies reported in scientific literature of a similar device for which equivalence to the device in question can be demonstrated; or

  3. c

     published or unpublished reports on other clinical experiences of either the device in question or a similar device for which equivalence to the device in question can be demonstrated;

• F25“coronavirus test device” means an in vitro diagnostic medical device for the detection of the presence of a viral antigen or viral ribonucleic acid (RNA) specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);

• “device for performance evaluation” means a product which is intended by its manufacturer to be subject to one or more performance evaluation studies in laboratories for medical analysis or in other appropriate environments outside his own premises;

• F106“Directive 90/385” means Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of Member States relating to active implantable devices;

• F125“Directive 93/42” means Council Directive 93/42/EEC of 14 June 1993 concerning medical devices;

• F130“Directive 98/79” means Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in-vitro diagnostic medical devices;

• “Directive 2001/83” means Directive 2001/83/EC of the European Parliament and of the Council of 6th November 2001 on the Community Code relating to medicinal products for human use F110F137as amended by Directive 2002/98/EC of the European Parliament and of the Council setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components, Commission Directive 2003/63/EC amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, Directive 2004/24/EC of the European Parliament and of the Council amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use and Directive 2004/27/EC of the European Parliament and of the Council amending Directive 2001/83/EC on the Community code relating to medicinal products for human use;

• F127“Directive 2003/12” means Commission Directive 2003/12 of 3rd February 2003 on the reclassification of breast implants in the framework of Directive 93/42/EEC concerning medical devices;

• F119...

• F138“Directive 2005/50” means Commission Directive 2005/50/EC of 11 August 2005 on the reclassification of hip, knee and shoulder joint replacements in the framework of Council Directive 93/42/EEC concerning medical devices;

• F107“Directive 2007/47” means Directive 2007/47/EC of the European Parliament and of the Council amending Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, Council Directive 93/42/EEC concerning medical devices and Directive 98/8/EC concerning the placing of biocidal products on the market;

• “Directive 2006/42/EC” means Directive 2006/42/EC of the European Parliament and of the Council on machinery;

• “F44... CAB” shall be construed in accordance with regulation 48(1);

• F141...

• F115“European Economic Area” means the European Economic Area created by the EEA Agreement;

• “harmonised standard” means—

  1. a

     a technical specification adopted, on a mandate from the European Commission, by the European Committee for Standardisation or the European Committee for Electrotechnical Standardisation, or by both of those bodies, in accordance with Directive 98/34/EC of the European Parliament and of the Council laying down a procedure for the provision of information in the field of technical standards and regulations F123, pursuant to the general guidelines on co-operation between the Commission and the said Committees signed on 13th November 1984; or

  2. b

     a monograph of the European Pharmacopoeia (in particular any monograph on surgical sutures and the interaction between medicinal products and materials used in medical devices containing medicinal products),

  the reference number of which has been published in the Official Journal of the F113European Union;

• F118“hazard” means a potential source of injury or damage to health;

• F117“hip, knee or shoulder replacement” means an implantable component part of a total joint replacement system which is intended to provide a function similar to that of either a natural hip joint, a natural knee joint or a natural shoulder joint, other than ancillary components (screws, wedges, plates and instruments);

• F140“intended for clinical investigation” means—

  1. a

     intended for use by a registered medical practitioner when conducting investigations of that device in an adequate human clinical environment; or

  2. b

     intended for use by any other person in a F33relevant state who, by virtue of their professional qualification, is authorised to carry out investigations of that device in an adequate human clinical environment;

• “intended purpose” means—

  1. a

     in relation to an active implantable medical device, the use for which it is intended and for which it is suited according to the data supplied by the manufacturer in the instructions relating to it;

  2. b

     in relation to any other medical device, the use to which the device is intended according to the data supplied by the manufacturer on the labelling, the instructions for use and/or the promotional materials;

• “in vitro diagnostic medical device” means a medical device which—

  1. a

     is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination; and

  2. b

     is intended by the manufacturer to be usedin vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information—

     1. i

        concerning a physiological or pathological state,

     2. ii

        concerning a congenital abnormality,

     3. iii

        to determine the safety and compatibility of donations, including blood and tissue donations, with potential recipients, or

     4. iv

        to monitor therapeutic measures,

     and includes a specimen receptacle but not a product for general laboratory use, unless that product, in view of its characteristics, is specifically intended by its manufacturer to be used forin vitro diagnostic examination;

• F124“machinery” has the meaning given to it by Article 2(a) of Directive 2006/42;

• “manufacturer” means—

  1. a

     the person with responsibility for the design, manufacture, packaging and labelling of a device before it is placed on the market under his own name, regardless of whether these operations are carried out by that person himself or on his behalf by a third party; or

  2. b

     any other person who assembles, packages, processes, fully refurbishes or labels one or more ready-made products or assigns to them their intended purpose as a device with a view to their being placed on the market under his own name, apart from a person who assembles or adapts devices already on the market to their intended purpose for an individual patient;

• F30“medical device” has the meaning given in Article 2(1) of Regulation (EU) 2017/745 and includes devices intended to administer a medicinal product or which incorporate as an integral part a substance which, if used separately, would be a medicinal product and which is liable to act upon the body with action ancillary to that of the device;

• “the Medical Devices Directives” means Directive 90/385, Directive 93/42, F121both read with Regulation (EU) No 207/2012 and Regulation (EU) No 722/2012 and Directive 98/79;

• F120...

• “medicinal product” has the meaning given in article 1.2 of Directive 2001/83;

• “Mutual Recognition Agreements” means the agreements, listed in Schedule 2, concluded between the European Community and States which are not part of the European Community on matters including the conditions under which each Party will accept or recognise the results of the conformity assessment procedures undertaken by the other Party’s designated bodies;

• “national standard” means a technical specification adopted by F82a relevant state which transposes, and corresponds to, a harmonised standard;

• F111...

• “notified body” means a body authorised in accordance with F128Part V or the Medical Devices Directives to carry out tasks of a notified body or the importing Party under the Medical Devices Directives or the Mutual Recognition Agreements in respect of a conformity assessment procedure;

• “placing on the market” means, in relation to a medical device, the first making available in return for payment or free of charge of a new or fully refurbished device, other than a device intended for clinical investigation, with a view to distribution, use, or both, on F72a relevant state market;

• “putting into service” means—

  1. a

     in relation to an active implantable medical device, the making available of the device to a registered medical practitioner for implantation;

  2. b

     in relation to any other medical device, the first making available of the device in F56a relevant state to a final user, including where a device is used in a professional context for the purposes of medical analysis without being marketed;

• F109“Regulation (EU) No 207/2012” means Commission Regulation (EU) No 207/2012 of 9 March 2012 on electronic instructions for use of medical devices;

• “Regulation (EU) No 722/2012” means Commission Regulation (EU) No 722/2012 of 8 August 2012 concerning particular requirements as regards the requirements laid down in Council Directives 90/385/EEC and 93/42/EEC with respect to active implantable medical devices and medical devices manufactured utilising tissues of animal origin;

• F5“Regulation (EU) 2017/745” means Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC;

• F144“Regulation (EU) 2017/746” means Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU;

• “Regulation (EU) 2022/1107” means Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 of the European Parliament and of the Council;

• “relevant essential requirements”, in relation to a medical device, means the essential requirements set out in Annex 1 of Directive 90/385, Annex I of Directive 93/42 or Annex I of Directive 98/79 which apply to it, but not including, in the case of a device intended for clinical investigation, such of those requirements, or aspects of them, as are the subject of the investigation;

• F27“relevant market” means a market of a relevant state;

• “relevant state” means—

  1. a

     in relation to any requirement relating to an in vitro diagnostic medical device, Northern Ireland or a Member State of the European Union;

  2. b

     in relation to any requirement relating to any other medical device, Northern Ireland or a state in the European Economic Area;

  3. c

     a State other than a Member State of the European Union which is a Party to an Association Agreement (where applicable under that Association Agreement);

• “specimen receptacle” means a medical device which (whether vacuum-type or not) is specifically intended by its manufacturer to be used for the primary containment and preservation of specimens derived from the human body for the purpose ofin vitro diagnostic examination;

• “stable derivatives device” means a medical device that contains human blood, blood products, plasma or blood cells of human origin, and which incorporates, as an integral part, a substance which—

  1. a

     if used separately, may be considered to be a medicinal product constituent or a medicinal product derived from human blood or human plasma within the meaning of article 1.10 of Directive 2001/83; and

  2. b

     is liable to act upon the human body with action ancillary to that of the device;

• “supply”, in relation to a medical device, means—

  1. a

     the supply of, or the offer or agreement to supply, the device; or

  2. b

     the exposure or possession for supply of the device;

• “third country conformity assessment body” means a body in a State which is not part of the Community that is designated in accordance with the Mutual Recognition Agreements to carry out tasks of a notified body under the conformity assessment procedures set out in the Medical Devices Directives;

• F116...

• F27“UK mutual recognition agreement” means an agreement between the United Kingdom and another country that covers matters including the conditions under which the United Kingdom and that country will accept or recognise the results of the conformity assessment procedures undertaken by each other’s designated bodies;

• “UK(NI) indication” means the marking in the form set out in Schedule 1 to the Product Safety and Metrology etc. (Amendment etc.) (UK(NI) indication) (EU Exit) Regulations 2020;

• “UK notified body” shall be construed in accordance with regulation 45; and

• F27“UK responsible person” is to be construed in accordance with regulation 19B(2) for the purposes of Part II, regulation 21C(2) for the purposes of Part III and regulation 44A(2) for the purposes of part IV.

F22Medical devices which are qualifying Northern Ireland goods2A

Scope of these RegulationsE23

Scope of these RegulationsE33

F94Revocation, transitional and saving provisions in respect of Regulation (EU) 2017/745 F148and Regulation (EU) 2017/7463ZA

F16Designated standard3A

ConfidentialityF743B

Transitional provisions4

F66Transitional provisions for hip, knee and shoulder replacements4A

F40Revocations, transitional and saving provisions in respect of the new national registration requirements4D

Revocation of Commission Decision 2002/364 on 26th May 2025 and its effect before that date4H

Revocation of Commission Decision 2010/2274I

F96Revocation of Commission Regulation (EU) No 207/2012 on 26th May 20254J

F70Revocation of Regulation (EU) No 722/2012 on 26th May 20254K

Revocation of Regulation (EU) No 920/2013 on 26th May 2025 and its effect before that date4L

Revocation of Regulation (EU) No 2017/2185 and saving provision4M

The classification criteria in Directives 2003/12 and 2005/50F114N

Revocation of Regulation (EU) 2017/7454O

Revocation of Regulation (EU) 2017/7464P

References in other legislation to Directives 90/385, 93/42 and 98/794T